Navigation Links
A Breakthrough in the Study of Hepatitis C

Finally, virus particles were examined by electron microscopy and shown to possess the expected size and shape of HCV virus particles.

Once the system was established, the group examined whether sera from patients carrying HCV could infect the human fetal hepatocytes. When sera from patients infected with different HCV strains were added to the hepatocyte culture system, viral replication occurred and new virus particles were produced.

In both transfection and infection models, virus particles were released in a cyclical manner, with bursts of virus produced every 10-14 days. This is similar to what has been reported during clinical HCV infection, possibly due to the host's natural defenses. Interestingly, cultured hepatocytes responded to viral replication by displaying signs of distress and cell death and by expressing interferon-beta, a cellular antiviral, in an effort to control the infection.

This culture system provides a breakthrough in studying HCV replication in nontransformed hepatocytes, the natural target of the virus. By allowing infection by patient serum containing a wide array of virus strains, this system may allow better understanding of the differences between different strains, further improving treatment strategies.

Source-Eurekalert
RI
'"/>




Page: 1 2

Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
3. Breakthrough in eye treatment
4. Genetic Breakthrough in Common Eye Problem
5. Breakthrough in cancer therapy
6. Breakthrough in Type II Diabetes
7. Breakthrough In Stem Cell Work
8. A Likely Breakthrough For Prostate Cancer Patients
9. New DNA Breakthrough Can Change Future Of Medicine
10. Breakthrough In New Vaccine For Malaria
11. Medical Breakthrough - Kidney Transplant Recipient Survives Without Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breakthrough the Study Hepatitis

(Date:12/2/2008)... Randomized Comparator Study to Evaluate Efficacy... , , WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswi...nounced that it plans to initiate the first clinic...citabine for injection) compared to Vidaza(R) (aza...ntermediate-2 or high-risk myelodysplastic syndrom...
(Date:12/2/2008)... DENVER, Dec. 2 Barotz Dental is ...fering LANAP(TM) (Laser Assisted New Attachment,P...rotocol that is patented,and FDA approved for new..., LANAP removes diseased tissue, without rem... tissue around teeth, minimizes pain and discomfor...
(Date:12/2/2008)... DENVER, Dec. 2 Global ...ompany") (OTC Bulletin Board: GLOB), an internatio...any, today announced that its,European subsidiary...on,Software, marketed as "Hemo Serveur" in France..."AP-HP") hospitals, representing 23,000 patient be...
(Date:12/2/2008)... FISHERS, Ind., Dec. 2 A number o... rise in childhood obesity, the health risks in,o...al value of cereals and,other foods kids consume....,-- offers all natural, freeze-dried real fruit pr...ids, but also provide most, if not all, of the dai...
Breaking Medicine News(10 mins):Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 3
...002, the number of drug users who completed the tr... of an increase in the number of people enrolling/...e more likely to drop out of treatment if they had...tem than if they had entered by other routes. This...
...ny Abbott yesterday accused the commonwealth of ba...ver how the public money was spent.// He attacke...d beggars" and blame-shifters who should be able t...he "river of gold" of GST receipts. State health...
...st producer of milk in the world but paradoxically...ren being the worst deprived, parliament was infor...ilk in India is 229 gm per day as against 887.7 gm...in Sweden, France (777.5) and Germany (741.52). I...
...utical Union (IPU) has insisted that the 'morning ...ounter to patients without a doctor's prescription...vonelle, has been licensed for use in Ireland sinc...must have a doctor's prescription. The pharmacists...
Other Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:The IPU Want Morning After Pills To Be Made Available Over The Counter 2
(Date:11/26/2008)...e-USNewswire/ -- Children whose eyes are misaligne... risk of developing mental illness by early adulth... published this month in Pediatrics , the official... , The retrospective study examined the medi...igned eyes) and compared them with records of chil...
(Date:11/26/2008)... , FRANKLIN, Mass., Nov. 26 /PRNewswire-FirstCa...) announced today that it has received full approv...) for its U.S. pivotal trial to study the effectiv...associated therapy in the prevention of Contrast-I...approved PLC,s request to expand their investigati...
(Date:11/25/2008)...-USNewswire/ -- Kleinert Kutz and University of L...hand transplant on Messina, New York resident, Jan...Hand Care Center on Monday, November 24. The inno...ed shortly after 9 p.m. in a record nine hours. ,...prnh/20081125/DC48555-a ) , (Photo: http://ww...
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3BioMarin Re Acquires Rights to Kuvan in Canada From Merck Serono 8454 1BioMarin Re Acquires Rights to Kuvan in Canada From Merck Serono 8454 2BioMarin Re Acquires Rights to Kuvan in Canada From Merck Serono 8454 3BioMarin Re Acquires Rights to Kuvan in Canada From Merck Serono 8454 4Dr Peter B Corr Joins Team at Celtic Therapeutics as General Partner 8450 1Dr Peter B Corr Joins Team at Celtic Therapeutics as General Partner 8450 2Dr Peter B Corr Joins Team at Celtic Therapeutics as General Partner 8450 3Dr Peter B Corr Joins Team at Celtic Therapeutics as General Partner 8450 4Laser Therapy Gives Smokers Hope for Successful New Years Resolution 2265 1Laser Therapy Gives Smokers Hope for Successful New Years Resolution 2265 2WellGen Inc Names Nancy E Rawson Ph D Chief Scientific Officer 2261 1WellGen Inc Names Nancy E Rawson Ph D Chief Scientific Officer 2261 2WellGen Inc Names Nancy E Rawson Ph D Chief Scientific Officer 2261 3
... SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ --...indings were presented from a,Phase 1b clinical tr...eukemia (B-CLL) at the American Society of Clinica...ncluded intravenous,administration of higher doses...ound that atacicept was well-tolerated and biologi...
... HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jun 4, 2007 - A...nnounced that the,Company presented a "meta-analys... Fampridine-SR in multiple sclerosis during a,post... and Research,in MS (ACTRIMS) Meeting in Washingto...lidation of Consistent Improvement in Walking,Spee...
Other Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 2Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 3Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 4
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: